Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma

Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We conducted a biomarker-driven trial of selumetinib (KOSELUGO™; ARRY-14...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Kenney, Cara, Kunst, Tricia, Webb, Santhana, Christina, Devisser, Arrowood, Christy, Steinberg, Seth M., Mettu, Niharika B., Kim, Edward J., Rudloff, Udo
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2021
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8068685/
https://ncbi.nlm.nih.gov/pubmed/33405090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01044-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars